Cognition Therapeutics(US:CGTX)2025-11-06 12:34Financial Performance - Cash, cash equivalents, and restricted cash equivalents as of September 30, 2025, were approximately $39.8 million, with total obligated grant funds remaining at $36.3 million[4] - The net loss for Q3 2025 was $4.9 million, or $(0.06) per basic and diluted share, compared to a net loss of $9.9 million, or $(0.25) per share in Q3 2024[7] - Total operating expenses for Q3 2025 were $6.4 million, down from $14.5 million in Q3 2024[10] - The accumulated deficit as of September 30, 2025, was $195.3 million, compared to $175.2 million at the end of 2024[10] Research and Development - Research and development expenses decreased to $3.8 million for Q3 2025, down from $11.4 million in Q3 2024, primarily due to the completion of clinical trials[5] - The company achieved over 75% enrollment in the Phase 2 'START' study of zervimesine in early Alzheimer's disease[6] - The proposed registrational Alzheimer's disease study design was accepted for presentation at the Clinical Trials in Alzheimer's Disease (CTAD) Conference scheduled for December 1-4, 2025[6] Funding and Capital - Cognition Therapeutics completed a $30 million registered direct offering of 14,700,000 shares of common stock to institutional investors[6] - Cognition Therapeutics has sufficient cash to fund operations and capital expenditures into the second quarter of 2027[4] Administrative Expenses - General and administrative expenses were $2.6 million for Q3 2025, compared to $3.1 million for the same period in 2024, driven by reduced stock-based compensation[7]